Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04686305 |
Title | Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC (DL03) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | Yes |
Sponsors | AstraZeneca |
Indications | |
Therapies |
Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan Carboplatin + Durvalumab + Trastuzumab deruxtecan |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | FRA | ESP | CAN | BEL |